09 November 2017

Launch of “Finger Stick” Sample Collection for EarlyCDT®-Lung

 

Simplified blood sample collection procedure expected to drive greater use of test for early detection of lung cancer in the US and open other markets

 

Nottingham, UK – 9 November 2017: Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announces it has validated and launched a finger stick collection capability for its EarlyCDT®-Lung test. The company believes this will increase utilisation of the test in the US and other territories as it expands its distribution in Europe and Asia.

“The benefit of early cancer detection is recognised by both physicians and patients but ease of use of the test along with cost and test performance, are also factors. The EarlyCDT-Lung test has the advantage of being a simple blood test, and can detect lung cancer up to four years earlier than other methods. It is also highly cost effective. By introducing finger stick blood collection we have created an option that will increase the speed and simplicity with which the EarlyCDT®-Lung test can be ordered and completed, with no loss of performance. We hope that this will make the test more accessible, especially in the US, so that more physicians and their patients will benefit from its ability to detect lung cancer early.”

Geoffrey Hamilton-Fairley

CEO of Oncimmune

Sample collection for EarlyCDT–Lung is simple but previously required a venous blood draw which for some physician practices in the US requires the patient to visit a medical center or blood draw center, and requires a trained phlebotomist to draw a venous sample. This adds costs, time and is sometimes inconvenient for patients. Using finger stick collection now gives physicians and patients the option to collect samples easily in the physician’s office or even in the patient’s home, thus making the entire process much simpler and quicker. Validation studies showed excellent results correlation between venous and finger stick sampling methods with no loss of signal or efficacy. Patients will still have the option of having a standard venous collection through a phlebotomist if this is their preference. 

 

As with many other tests the finger stick simply requires the patient to pierce the skin of the finger using the contact activated lancet that is supplied and then collect sufficient blood drops into a small collection tube that is returned to Oncimmune in a bag supplied. Once submitted to Oncimmune’s CLIA-certified laboratory in Kansas, the result is reported to the physician in two to five days.

 

For further information:

 

Oncimmune Holdings plc

Geoffrey Hamilton-Fairley, Chief Executive Officer

contact@oncimmune.co.uk

 

 

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Matthew Neal, Lindsey Neville

oncimmune@consilium-comms.com

+44 (0) 20 3709 5708

 

For US media enquiries, please contact:

TJS Communications, Inc.

Tonua Fedusenko

+1 207 937 2243

 

About Oncimmune

Oncimmune is a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company's first product, EarlyCDT®-Lung, was launched in 2012, as a CLIA test in the USA and since then over 150,000 commercial tests have been sold. EarlyCDT®-Lung is available through physicians in the US and also privately in the UK and other regions. EarlyCDT®-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,210 high-risk smokers. EarlyCDT® tests for liver and ovarian cancer are in development.

 

Oncimmune, headquartered in Nottingham, United Kingdom with testing facilities in the US, joined AIM in May 2016 under the ticker ONC.L. For more information, visit www.oncimmune.com

 


Back to previous page